Palantir's AI Crown Slips as Rivalry and Geopolitics Collide

Palantir faces a triple threat: AI rival Anthropic's explosive growth, major insider stock sales, and a fading geopolitical 'war premium' pressuring its premium valuation.

Palantir Technologies Inc. is facing its most significant market pressure in a year, with its stock plummeting over 14% in a single week. This dramatic sell-off underscores a harsh reassessment of the data analytics firm's premium valuation, triggered by a potent combination of surging competition, insider skepticism, and shifting geopolitical winds.

The immediate catalyst for investor anxiety is the explosive growth of AI startup Anthropic. Reports indicate the rival's annual recurring revenue skyrocketed from $9 billion at the end of 2025 to $30 billion in just the first four months of 2026. This blistering pace has fueled concerns that Anthropic is rapidly eroding the market share of established players like Palantir. These fears were amplified by prominent short-seller Michael Burry, who doubled his put options against Palantir. In a since-deleted post, Burry argued Anthropic is running circles around the company and pegged Palantir's true value below $50 per share.

This external pressure coincides with notable retreats from within. Over the past 90 days, company insiders, including CEO Alexander Karp, sold shares worth approximately $137.7 million. Institutional investors also pared back their stakes in Q4 2025, with Carnegie Investment Counsel reducing its position by 5.1% to 112,445 shares and Bouvel Investment Partners slashing its holding by 44.7% to 26,208 shares.

Beyond the competitive battlefield, a key narrative supporting Palantir's stock is dissolving. Recent diplomatic efforts toward a ceasefire in the Middle East are deflating the so-called "war premium" that had long buoyed the share price. While the Pentagon plans to fully integrate Palantir's "Maven" military AI system by the end of 2026, the prospect of geopolitical de-escalation is dampening near-term revenue fantasies from the defense sector. This shifts the entire burden of justifying the stock's lofty valuation—with a forward price-to-earnings ratio as high as 108—squarely onto its commercial business.

On that commercial front, the signals are mixed but robust. The company's most recent quarterly report showed U.S. commercial revenue surging 137% year-over-year, with the number of deals worth over $10 million jumping 91%. Analyst Dan Ives of Wedbush remains a staunch bull, maintaining a $230 price target and dismissing the Anthropic threat as overblown due to Palantir's fundamentally different business model focused on building digital twins for enterprise decision-making.

However, new controversies are emerging that could threaten future government contracts, a segment currently worth over $900 million. Reports surfaced over the weekend that engineers gained access to a directory containing data on 1.5 million employees of Britain's National Health Service (NHS), reigniting longstanding data privacy debates.

The stock closed Friday at €108.84, unable to sustain a brief rally sparked by a supportive post from former President Donald Trump on Truth Social. With its recent strong quarterly profit of $0.25 per share now overshadowed, all eyes are on the upcoming Q1 2026 report. This release will be the next crucial test, quantifying Palantir's actual operational growth in a newly competitive and less geopolitically charged environment.